LJPCのニュース
Are Investors Eager To Sell Holdings In La Jolla Pharmaceutical Company (NASDAQ: LJPC)? 2022/08/17 20:00:00 Stocks Register
La Jolla Pharmaceutical Company (NASDAQ:LJPC) price is hovering lower on Tuesday, August 16, dropping -2.34% below its previous close. A look at today’s price movement shows that the recent level at last check reads $6.20, with intraday deals fluctuating between $6.19 and $6.22. The company’s 5Y monthly beta was ticking 1.97 while its P/E ratio … Are Investors Eager To Sell Holdings In La Jolla Pharmaceutical Company (NASDAQ: LJPC)? Read More »
Equity Alert - The M&A Class Action Firm Announces the Investigation of La Jolla Pharmaceutical Co. - LJPC 2022/07/16 05:14:00 PR Newswire
NEW YORK, July 16, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered…
Dow Dips Around 90 Points; La Jolla Pharmaceutical Shares Surge 2022/07/11 18:42:13 Benzinga
U.S. stocks traded lower toward the end of trading as investors digested the recent jobs report for the month of June. The Dow traded down 0.30% to 31,242.86 while the NASDAQ fell 1.85% to 11,419.99. The S&P also fell, dropping, 0.92% to 3,863.48. Also check this: GameStop, Levi Strauss And 3 Stocks To Watch Heading Into Friday Leading and Lagging Sectors Utilities shares rose by 0.3% on Monday. Meanwhile, top gainers in the sector included Enel Chile SA - ADR (NYSE: ENIC ), up 3% and UGI Corp (NYSE: UGI ) up 2%. In trading on Monday, communication services shares dipped by 2.6%. Top Headline AZZ Inc (NYSE: AZZ ) reported better-than-expected earnings for its first quarter on Monday. AZZ reported first-quarter FY23 sales growth of 36.8% year-over-year to $314.4 million, beating the consensus of $268.09 million. Adjusted EPS jumped 59.1% Y/Y to $1.40, beating the consensus of $1.03. Equities Trading UP Pliant Therapeutics, Inc. (NASDAQ: PLRX ) shares shot up 125% to $20.00 after the company said its treatment for Idiopathic Pulmonary …
BLI, GNFT and AWH among mid-day movers 2022/07/11 16:52:12 Seeking Alpha
Gainers: Pliant Therapeutics PLRX +114%.Kaspien Holdings (KSPN) +99%.Iterum Therapeutics ITRM +83%.La Jolla Pharmaceutical Company LJPC +81%.Digital World Acquisition…
Why These Casino Stocks Are Moving Lower, Here''s 45 Stocks Moving In Monday''s Mid-Day Session 2022/07/11 16:11:18 Benzinga
Gainers Pliant Therapeutics, Inc. (NASDAQ: PLRX ) jumped 112.6% to $18.88 after the company said its treatment for Idiopathic Pulmonary Fibrosis was well tolerated in a Phase 2a study. La Jolla Pharmaceutical Company (NASDAQ: LJPC ) gained 80.9% to $6.13 after Innoviva entered into a definitive agreement to acquire the company for $5.95 per share and an incremental $0.28 per share for additional cash proceeds, or an implied enterprise value of approximately $149 million. Iterum Therapeutics plc (NASDAQ: ITRM ) surged 71.8% to $0.4124 after the company announced that it has reached an agreement with the FDA under the special protocol assessment process on the design, endpoints and statistical analysis of a Phase 3 clinical trial for oral sulopenem etzadroxil-probenecid to begin in Q4. Kaspien Holdings Inc. (NASDAQ: KSPN ) jumped 39.6% to $3.63. Volcon, Inc. (NASDAQ: VLCN ) gained 32.5% to $2.1299. Volcon received thousands of non-binding pre-production orders, which, if finalized, would result in more than $70 million worth of revenue following delivery.
Are Investors Eager To Sell Holdings In La Jolla Pharmaceutical Company (NASDAQ: LJPC)? 2022/08/17 20:00:00 Stocks Register
La Jolla Pharmaceutical Company (NASDAQ:LJPC) price is hovering lower on Tuesday, August 16, dropping -2.34% below its previous close. A look at today’s price movement shows that the recent level at last check reads $6.20, with intraday deals fluctuating between $6.19 and $6.22. The company’s 5Y monthly beta was ticking 1.97 while its P/E ratio … Are Investors Eager To Sell Holdings In La Jolla Pharmaceutical Company (NASDAQ: LJPC)? Read More »
Equity Alert - The M&A Class Action Firm Announces the Investigation of La Jolla Pharmaceutical Co. - LJPC 2022/07/16 05:14:00 PR Newswire
NEW YORK, July 16, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered…
Dow Dips Around 90 Points; La Jolla Pharmaceutical Shares Surge 2022/07/11 18:42:13 Benzinga
U.S. stocks traded lower toward the end of trading as investors digested the recent jobs report for the month of June. The Dow traded down 0.30% to 31,242.86 while the NASDAQ fell 1.85% to 11,419.99. The S&P also fell, dropping, 0.92% to 3,863.48. Also check this: GameStop, Levi Strauss And 3 Stocks To Watch Heading Into Friday Leading and Lagging Sectors Utilities shares rose by 0.3% on Monday. Meanwhile, top gainers in the sector included Enel Chile SA - ADR (NYSE: ENIC ), up 3% and UGI Corp (NYSE: UGI ) up 2%. In trading on Monday, communication services shares dipped by 2.6%. Top Headline AZZ Inc (NYSE: AZZ ) reported better-than-expected earnings for its first quarter on Monday. AZZ reported first-quarter FY23 sales growth of 36.8% year-over-year to $314.4 million, beating the consensus of $268.09 million. Adjusted EPS jumped 59.1% Y/Y to $1.40, beating the consensus of $1.03. Equities Trading UP Pliant Therapeutics, Inc. (NASDAQ: PLRX ) shares shot up 125% to $20.00 after the company said its treatment for Idiopathic Pulmonary …
BLI, GNFT and AWH among mid-day movers 2022/07/11 16:52:12 Seeking Alpha
Gainers: Pliant Therapeutics PLRX +114%.Kaspien Holdings (KSPN) +99%.Iterum Therapeutics ITRM +83%.La Jolla Pharmaceutical Company LJPC +81%.Digital World Acquisition…
Why These Casino Stocks Are Moving Lower, Here''s 45 Stocks Moving In Monday''s Mid-Day Session 2022/07/11 16:11:18 Benzinga
Gainers Pliant Therapeutics, Inc. (NASDAQ: PLRX ) jumped 112.6% to $18.88 after the company said its treatment for Idiopathic Pulmonary Fibrosis was well tolerated in a Phase 2a study. La Jolla Pharmaceutical Company (NASDAQ: LJPC ) gained 80.9% to $6.13 after Innoviva entered into a definitive agreement to acquire the company for $5.95 per share and an incremental $0.28 per share for additional cash proceeds, or an implied enterprise value of approximately $149 million. Iterum Therapeutics plc (NASDAQ: ITRM ) surged 71.8% to $0.4124 after the company announced that it has reached an agreement with the FDA under the special protocol assessment process on the design, endpoints and statistical analysis of a Phase 3 clinical trial for oral sulopenem etzadroxil-probenecid to begin in Q4. Kaspien Holdings Inc. (NASDAQ: KSPN ) jumped 39.6% to $3.63. Volcon, Inc. (NASDAQ: VLCN ) gained 32.5% to $2.1299. Volcon received thousands of non-binding pre-production orders, which, if finalized, would result in more than $70 million worth of revenue following delivery.
La Jolla Pharmaceutical GAAP EPS of $0.11 beats by $0.07, revenue of $12.2M misses by $1.83M 2022/03/09 14:11:06 Seeking Alpha
La Jolla Pharmaceutical press release (LJPC): Q4 GAAP EPS of $0.11 beats by $0.07.Revenue of $12.2M (+10.9% Y/Y) misses by $1.83M.Shares +5.47%.
La Jolla Pharmaceutical (NASDAQ:LJPC) Upgraded by Zacks Investment Research to Buy 2021/12/18 09:54:42 Dakota Financial News
Zacks Investment Research upgraded shares of La Jolla Pharmaceutical (NASDAQ:LJPC) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning, Zacks.com reports. They currently have $5.00 price objective on the biopharmaceutical companys stock. According to Zacks, LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development []
La Jolla Pharmaceutical (NASDAQ:LJPC) Downgraded by Zacks Investment Research 2021/12/14 06:36:42 Dakota Financial News
La Jolla Pharmaceutical (NASDAQ:LJPC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. “ NASDAQ:LJPC opened […]
La Jolla Pharmaceutical Company (NASDAQ: LJPC) Rise 5.08%, Now What? Dont Panic 2021/12/11 20:00:00 Stocks Register
La Jolla Pharmaceutical Company (NASDAQ:LJPC) price on Friday, December 10, rose 5.08% above its previous days close as an upside momentum from buyers pushed the stocks value to $4.55. A look at the stocks price movement, the close in the last trading session was $4.33. The beta value (5-Year monthly) was 2.36 while the PE La Jolla Pharmaceutical Company (NASDAQ: LJPC) Rise 5.08%, Now What? Dont Panic Read More »
La Jolla Pharmaceutical (NASDAQ:LJPC) Rating Increased to Buy at Zacks Investment Research 2021/12/08 06:08:42 ETF Daily News
Zacks Investment Research upgraded shares of La Jolla Pharmaceutical (NASDAQ:LJPC) from a hold rating to a buy rating in a report released on Saturday, Zacks.com reports. The brokerage currently has $4.25 price target on the biopharmaceutical companys stock. According to Zacks, LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products [] The post La Jolla Pharmaceutical (NASDAQ:LJPC) Rating Increased to Buy at Zacks Investment Research appeared first on ETF Daily News .